drugset / Trial / NCT00605423
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
Phase 2
Completed
6 enrolled
Johns Hopkins University
Alimera Sciences · collabpSiVida Limited · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be required to maintain this effect. It is hypothesized that sustained release fluocinolone acetonide will allow maintenance of the improved vision with fewer Lucentis injections.
Timeline
- Start
- 2008-01
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | fluocinolone acetonide | Small molecule | 0.2 ug | — |
| Comparator | fluocinolone acetonide | Small molecule | 0.5 ug | — |